Agios Pharmaceuticals

Agios Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Agios Pharmaceuticals excels in Q4, eyes hematology franchise expansion

Agios Pharmaceuticals showcased strong performance and progress in its Q4 2022 earnings call, emphasizing advancements in its pipeline and commercial capabilities. While facing challenges in estimating sales and patient enrollment progression, the company is well-positioned to capitalize on opportunities for growth and expansion.

Agios Pharmaceuticals reports robust Q1 earnings and strategic growth outlook

Agios Pharmaceuticals demonstrated strong financial performance, progress in PK activation therapies, and strategic decision-making in Q1 2023.
While facing challenges in distribution and inventory management, the company's focus on persistency, clear milestones, and launch dynamics present growth opportunities.
Overall, Agios Pharmaceuticals is well-positioned to capitalize on its strengths, address challenges, and leverage opportunities for future success.

Agios Pharmaceuticals reports strong Q2 performance and eyes growth opportunities

Agios Pharmaceuticals shows strong financial performance and pipeline progress.
Challenges include slow uptake for PYRUKYND and clinical development queries.
Exciting opportunities lie in potential acquisitions, peak sales targets, and upcoming data readouts.

Agios Pharmaceuticals excels in Q3, poised for growth and innovation

Agios Pharmaceuticals delivered a strong performance in Q3 2023, achieving key milestones and reporting solid financial results, positioning the company for future growth.
With a focus on pipeline advancements, commercial success, and financial stability, Agios demonstrates resilience and potential in the competitive pharmaceutical landscape.
While facing challenges in competitive markets and the need for further clarity on certain aspects, Agios has opportunities to capitalize on its strengths and drive innovation and growth.

Agios Pharmaceuticals reports robust earnings and eyes market expansion

Agios Pharmaceuticals showcased strong performance in PK activator development, with positive data readouts and financial stability driving growth prospects.
While facing challenges in market differentiation and regulatory approval, the company's strategic strengths in rare disease treatments and operational efficiency position it for long-term success.
With upcoming launches for thalassemia and sickle cell disease, Agios has opportunities to expand its market presence, drive revenue growth, and establish itself as a key player in rare disease therapeutics.

Agios Pharmaceuticals excels in Q1, eyes strong growth opportunities

Agios Pharmaceuticals showcased strong performance with positive clinical data and solid financials.
While facing challenges in market dynamics and cost management, the company is optimistic about future opportunities.
With a focus on partnerships and revenue growth, Agios aims to deliver value to shareholders.
The company's robust pipeline and cash position position it well for future success.

Agios Pharmaceuticals reports robust Q3 performance and eyes future launches

Agios Pharmaceuticals showcased strong financial performance and progress in key therapeutic areas during their Q3 2024 earnings call. While facing challenges in addressing analyst inquiries and market comparisons, the company remains optimistic about their future prospects. Leveraging their strengths in market engagement and scientific innovation, Agios is well-positioned for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Agios Pharmaceuticals (AGIO) agrees to sell to Royalty Pharma the rights to royalties on potential net sales of a brain cancer drug that was sold to Servier in 2021.

Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty

Agios agreed Tuesday to sell its 15% royalty in a brain cancer drug for $905 million upfront. Agios stock is poised to break out at the open.

Agios Pharmaceuticals Inks $905 Million Deal For Cancer Drug; Shares Poised To Break Out

The mean of analysts' price targets for Agios Pharmaceuticals (AGIO) points to a 26.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

How Much Upside is Left in Agios Pharmaceuticals (AGIO)? Wall Street Analysts Think 26.43%

– Data from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia to be Presented in Plenary Session –

Agios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid Congress

The consensus price target hints at a 26% upside potential for Agios Pharmaceuticals (AGIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 26.01% Upside in Agios Pharmaceuticals (AGIO): Can the Stock Really Move This High?

Agios (AGIO) reports mixed earnings results for first-quarter 2024. Though sales miss the mark, revenues from its sole marketed drug, Pyrukynd, rise sequentially and on a yearly basis.

Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates

CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company is scheduled to present at the 2024 RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 8:00 a.m. ET.

Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q1 2024 Earnings Conference Call May 2, 2024 8:00 AM ET Company Participants Chris Taylor - Vice President, Investor Relations and Corporate Communications Brian Goff - Chief Executive Officer Sarah Gheuens - Chief Medical Officer and Head, R&D Tsveta Milanova - Chief Commercial Officer Cecilia Jones - Chief Financial Officer Conference Call Participants Gregory Renza - RBC Capital Markets Divya Rao - TD Cowen Eric Schmidt - Cantor Alec Stranahan - Bank of America Tessa Romero - JPMorgan Danielle Brill - Raymond James Operator Good morning, and welcome to Agios' First Quarter 2024 Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded at Agios' request.

Agios Pharmaceuticals, Inc. (AGIO) Q1 2024 Earnings Call Transcript

Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.45 per share versus the Zacks Consensus Estimate of a loss of $1.64. This compares to loss of $1.47 per share a year ago.

Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates

– Topline Data Readout from the Phase 3 ENERGIZE-T Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia now expected in Q2 2024 –

Agios Reports Business Highlights and First Quarter 2024 Financial Results

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for

CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, May 2, 2024, at 8:00 a.m. ET to report its first quarter 2024 financial results and other business highlights.

Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024

Amgen

Ocular Therapeutix

Some of the hottest opportunities can be found in biotech stocks to buy now. With innovation, mergers and acquisitions, major companies looking to replenish their pipelines ahead of patent expirations, treatments for obesity, aging baby boomers, and demand for better care are creating massive opportunities.

The 3 Best Biotech Stocks to Buy Now: Q2 Edition

CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company is scheduled to present at the Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024, at 10:00 a.m.

Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024

CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company is scheduled to present at the TD Cowen 44th Annual Health Care Conference on Monday, March 4, 2024, at 2:10 p.m.

Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024

Agios' (AGIO) earnings and revenues miss estimates in the fourth quarter of 2023. Revenues from its sole marketed drug, Pyrukynd, rise year over year.

Agios (AGIO) Q4 Earnings & Revenues Fall Short of Estimates

Agios Pharmaceuticals (AGIO) Q4 2023 Earnings Call Transcript

Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.72 per share versus the Zacks Consensus Estimate of a loss of $1.64. This compares to earnings of $0.67 per share a year ago.

Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Misses Revenue Estimates

– Announced Positive Results from the Phase 3 ENERGIZE Study of Mitapivat in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia – – Presented Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition – – Two Additional Phase 3 Readouts of Mitapivat Expected in 2024, with a Total of Four Phase 3 Readouts by the End of 2025 – – U.S. PYRUKYND ® (mitapivat) Net Revenue of $7.1 Million in Q4; Cash, Cash Equivalents and Marketable Securities of $806.4 Million as of December 31, 2023 – CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2023.

Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Alkermes

Arrowhead Pharmaceuticals

Biogen

BioMarin Pharmaceutical

Bristol-Myers

Gilead Sciences

Unlike many other market segments, biotech stocks stand out for their direct relevance. For example, investors who typically wager on aerospace and defense plays usually aren't fighter pilots.

7 Biotech Stocks Fighting America's Deadliest Diseases

Earnings Preview: Agios Pharmaceuticals (AGIO) Q4 Earnings Expected to Decline

CAMBRIDGE, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, February 15, 2024, at 8:00 a.m. ET to report its fourth quarter and year end 2023 financial results and other business highlights.

Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024

Agios Pharmaceuticals, Inc. announced positive data from its Thalassemia trial in non-transfusion dependent patients. The company plans to file NDAs based on the trial results by the end of 2024, with potential approval in 2025. Agios is expected to have multiple approvals in 2025, including for sickle cell disease, which is a larger market.

Agios Is A Gem, But It Will Need Patience (Rating Upgrade)

– Industry-leading PK Activator Franchise Has Demonstrated Clinical Efficacy in Four Hematological Diseases, Including New Positive Phase 3 Data in Non-Transfusion-Dependent Thalassemia –

Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio

Agios Pharmaceuticals completed its IPO in 2013 and sold its oncology portfolio for $1.8bn in 2021. Its stock price is down 50% across a 5-year period. The company's focus is now on mitapivat, which has been approved for hemolytic anemia and is being studied for thalassemia and sickle cell disease. Positive results from the Phase 3 study of mitapivat in thalassemia suggest a potential approval in 2025 and a larger market opportunity.

News for Agios Pharmaceuticals Stock (AGIO)